Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Medical Specialties
Employees:
755
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Veracyte Inc market cap is $2.03B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Veracyte Inc 52 week high is $60.91 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Veracyte Inc 52 week low is $21.91 as of November 22, 2026.
Veracyte Inc stock price today is $25.13.
Veracyte Inc stock price yesterday was $25.04.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Veracyte Inc's P/E ratio is 16.21.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Veracyte Inc P/B ratio is 1.4142.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Veracyte Inc 50-day moving average is $40.41.